|
C. R. Bard has reported an increase in net income for the fiscal year 2009, despite an earnings dip in the 2009 fourth quarter that ended Dec. 31.
C. R. Bard has received pre-market approval from the FDA to market its LifeStent FlexStar and FlexStar XL vascular stent systems for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries.
|
C. R. Bard has reported growth in net income and net sales for its 2009 first quarter driven by reductions in distributor inventory and by managing expenses.
C. R. Bard has received approval from the FDA to market the E*Luminexx vascular stent, a self-expanding nitinol stent to be marketed by the Bard Peripheral Vascular Division of Tempe, Ariz.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).